For years, the vaping industry sold a simple promise: a cleaner alternative to combustible cigarettes. Millions bought in. Now, a sweeping new review of the scientific literature is challenging that narrative with uncomfortable force, concluding that e-cigarette use carries measurable cancer risks that can no longer be waved away as theoretical.
The findings, published in the journal Cancer by researchers at the University of Colorado Anschutz Medical Campus, synthesize evidence from dozens of studies examining the biological effects of vaping on human tissue. The conclusion is stark. E-cigarettes cause DNA damage, trigger inflammatory responses, and produce epigenetic changes — the kind of molecular disruptions that are well-established precursors to malignancy. As Gizmodo reported, the review found that while the cancer risk from vaping is likely lower than that from traditional cigarettes, it is far from negligible — and for people who never smoked at all, picking up an e-cigarette represents a net increase in cancer risk, full stop.
That distinction matters enormously. The public health calculus around vaping has always hinged on a comparison: vaping versus smoking. And within that narrow frame, e-cigarettes do appear less harmful. But the frame itself has been too narrow. A generation of young people who might never have touched a cigarette now inhale aerosolized nicotine laced with volatile organic compounds, heavy metals, and carbonyl compounds like formaldehyde and acrolein. For them, the relevant comparison isn’t vaping versus smoking. It’s vaping versus nothing.
“The ‘safer than cigarettes’ argument has been used as a shield for too long,” said Dr. Deepak Kademani, a head and neck surgeon and cancer researcher not involved in the review, in comments to media outlets covering the findings. “Safer does not mean safe.”
The University of Colorado team, led by Dr. Úrsula Salazar Bañuelos, examined studies spanning cell cultures, animal models, and human clinical data. What emerged was a consistent pattern across multiple organ systems. In the oral cavity and lungs — the tissues most directly exposed to e-cigarette aerosol — researchers found elevated markers of oxidative stress, chronic inflammation, and impaired DNA repair mechanisms. These aren’t speculative concerns. They are the same biological pathways implicated in the development of squamous cell carcinomas and adenocarcinomas caused by tobacco smoke.
One of the more alarming findings involves the bladder. Several studies included in the review detected higher concentrations of known carcinogenic metabolites in the urine of vapers compared to non-users. The implications are significant. Bladder cancer has long been associated with smoking, and the presence of similar metabolic byproducts in vapers suggests that the carcinogenic reach of e-cigarettes extends well beyond the respiratory tract.
And then there’s the issue of flavoring compounds. The review highlights growing evidence that the chemical additives used to create flavors — vanilla, mint, fruit, candy — aren’t inert bystanders. When heated, many of these compounds undergo thermal decomposition into toxic byproducts. Diacetyl, the buttery flavoring agent already infamous for causing “popcorn lung” in factory workers, is just one example. Others, less well-known, are now under scrutiny for their genotoxic potential. The sheer variety of flavoring chemicals on the market — thousands of formulations with minimal regulatory oversight — makes comprehensive risk assessment extraordinarily difficult.
This regulatory gap is not accidental. The FDA has struggled for over a decade to impose meaningful controls on the e-cigarette market. While the agency technically gained authority over e-cigarettes in 2016 through the Deeming Rule, enforcement has been inconsistent and frequently delayed. Millions of flavored products remained on shelves for years without completing the premarket review process. Juul, the company that came to symbolize the youth vaping epidemic, only recently saw its products face serious regulatory action — and even that was tangled in legal challenges.
The timing of this new review is notable. It arrives as vaping rates among American teenagers, after declining modestly in recent years, remain stubbornly high. According to the most recent National Youth Tobacco Survey, roughly 1.6 million middle and high school students reported current e-cigarette use in 2024. Disposable devices, many imported from China and sold in violation of FDA marketing orders, continue to flood the market. The flavors — Blue Razz, Watermelon Ice, Mango Peach — are not designed for forty-year-old smokers trying to quit.
The cancer review also raises questions about the long-term trajectory of disease that may not manifest for decades. Cancer is a slow-moving catastrophe at the cellular level. The lag time between exposure and diagnosis for tobacco-related cancers is typically 20 to 30 years. E-cigarettes have only been widely used for about 15 years. We are, in a sense, still in the early innings. The molecular evidence documented in the review — the DNA strand breaks, the methylation changes, the upregulation of oncogenes — represents the biological groundwork being laid right now for cancers that may not appear until the 2040s or 2050s.
“We’re seeing the smoke before the fire,” Dr. Salazar Bañuelos told reporters. “The cellular damage is already there. The question is not if some of these users will develop cancer, but how many.”
Not everyone agrees with the most dire interpretations. Some harm-reduction advocates argue that focusing on the cancer risks of vaping without adequate context could drive current vapers back to combustible cigarettes — a clearly worse outcome. Dr. Michael Siegel, a public health researcher at Tufts University who has long supported e-cigarettes as a cessation tool, has cautioned against overstating the risks. He and others point to Public Health England’s oft-cited estimate that vaping is roughly 95% less harmful than smoking, though that figure has itself been criticized as based on limited evidence and expert opinion rather than hard epidemiological data.
The tension is real and unresolved. For a 50-year-old pack-a-day smoker who switches entirely to vaping, the trade-off probably favors the e-cigarette. But that population is not the one driving growth in the vaping market. The fastest-growing user base is young, has never smoked, and is absorbing nicotine and chemical aerosols during a period of active biological development. The review in Cancer makes clear that for this group, the risk-benefit equation tilts decisively in the wrong direction.
There’s a broader institutional failure here, too. The American medical establishment was slow to sound the alarm on cigarettes in the mid-20th century, even as internal industry documents revealed that tobacco companies knew their products were carcinogenic. The parallels with vaping aren’t exact — e-cigarette companies haven’t been caught suppressing cancer research in the same way — but the pattern of regulatory delay, industry obfuscation, and public complacency rhymes uncomfortably.
Recent coverage from The New York Times noted that the new review has already prompted calls from several oncology professional organizations for updated clinical guidelines on screening vapers for early signs of oral, lung, and bladder cancers. The American Association for Cancer Research issued a statement urging the FDA to accelerate its review of pending e-cigarette applications and to strengthen enforcement against unauthorized products.
Meanwhile, the global picture is equally complicated. In the United Kingdom, regulators have taken a markedly different approach, actively promoting vaping as a smoking cessation tool and even distributing e-cigarettes through the National Health Service. But even British health authorities have begun recalibrating. The UK’s Medicines and Healthcare products Regulatory Agency announced earlier this year that it would tighten rules on disposable vapes and limit nicotine concentrations, acknowledging rising concern about youth uptake and emerging health data.
So where does this leave the roughly 9 million American adults who currently vape? In an uncomfortable gray zone. The evidence doesn’t yet support the claim that vaping causes cancer at rates comparable to smoking. But it does support the claim that vaping causes the kind of cellular damage that, over time, leads to cancer. The difference is one of degree and latency, not of kind.
For clinicians, the review offers a framework. Ask patients about vaping. Don’t assume it’s benign. Screen accordingly. For policymakers, the message is more urgent: the regulatory apparatus governing e-cigarettes remains woefully inadequate for the scale of the public health experiment currently underway. And for the millions of young people who picked up a vape pen believing it was harmless — the science is catching up, and what it’s finding should give everyone pause.
The promise was clean. The reality is turning out to be considerably more complicated.
WebProNews is an iEntry Publication